The European Pharmaceutical Wholesale Industry: - phagro

More documents

Recommendations

Info

The European Pharmaceutical Wholesale Industry � Consequently, wholesalers’ margins will face a further decline due to lower manufacturing prices and changes in the assortment towards a larger share of low-price generic products. � For wholesalers, the situation becomes dramatic, since margins are decreasing and, at the same time, the number of services offered to manufacturers and pharmacies is increasing. � The range of services offered is not only a consequence of competition, but is also determined by public service obligations. Thus, costs of many services offered are (or are likely to become) not covered by margins anymore. � In the past, wholesalers reacted to these challenges by restructuring their business-processes. Although the use of information and automation technologies, as well as outsourcing-strategies has helped them to reduce operating cost, the space for rationalization is already becoming narrower. � Other strategies, like horizontal integration, are also reaching their limits, as competition laws restrict further mergers and acquisitions in some European countries. � Entering new markets, especially the retail markets, offered wholesalers the chance to improve their efficiency and competitiveness. Again, competition laws more and more prove to set a limit to forward integration. � A third strategy that could improve the wholesalers’ situation would involve the regional expansion of pharmaceutical wholesalers. Currently, pharmaceutical wholesaling is predominantly a national business, since a single market for pharmaceuticals is far from being achieved. The reduction of market entry barriers e.g. in form of divergent pricing regulations could help to improve the efficiency of pharmaceutical distribution. � So, from a policy-making point of view, reducing public spending on pharmaceuticals by simply reducing margins for distributors seems to be too shortsighted. More consciousness on the costs occurring in the distribution of medicines would be desirable. � In close cooperation with supply chain partners and with national and EU health care authorities full-line wholesalers could contribute in efforts to reallocate and therefore optimize health care expenditure. The nomination of GIRP as one of 10 permanent members in the new G-10 process is an important step towards integrating supply chain issues into overall health care policy considerations. IX IPF Institute for Pharmaeconomic Research
The European Pharmaceutical Wholesale Industry IPF Institute for Pharmaeconomic Research X
Page 1: ��
Page 4 and 5: Contents a The European Pharmaceuti
Page 6 and 7: Figures c The European Pharmaceutic
Page 8 and 9: The European Pharmaceutical Wholesa
Page 10 and 11: III The European Pharmaceutical Who
Page 12 and 13: V The European Pharmaceutical Whole
Page 14 and 15: VII The European Pharmaceutical Who
Page 18 and 19: 1 Introduction 1 The European Pharm
Page 22 and 23: 5 The European Pharmaceutical Whole
Page 28 and 29: 11 The European Pharmaceutical Whol
Page 40 and 41: 23 75 74 73 72 71 70 The European P
Page 60 and 61: 43 40 35 30 25 20 15 10 5 0 The Eur
Page 66 and 67:
49 The European Pharmaceutical Whol
Page 68 and 69:
Page 70 and 71:
The European Pharmaceutical Wholesa
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
9 Bibliography 69 The European Phar
show all

The European Pharmaceutical Wholesale Industry: - phagro

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?